Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness and Safety of Intravenous Infusion of Bone Marrow Derived Allogeneic Multipotent Mesenchymal Stromal Cells for Enhancing Hematopoietic Recovery and Prophylaxis of Neutropenic Enterocolitis in Hematological Patients With Aplasia After High-dose Chemotherapy.

NCT02145923 is registered in ClinicalTrials.gov with Burnasyan Federal Medical Biophysical Center as lead sponsor.

NCT NCT02145923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02145923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness and Safety of Intravenous Infusion of Bone Marrow Derived Allogeneic Multipotent Mesenchymal Stromal Cells for Enhancing Hematopoietic Recovery and Prophylaxis of Neutropenic Enterocolitis in Hematological Patients With Aplasia After High-dose Chemotherapy.
Lead sponsor
Burnasyan Federal Medical Biophysical Center
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 31, 2014
Completion date
December 31, 2016
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myeloablative chemotherapy induced bone marrow aplasia, neutropenic enterocolitis